A PTN-Rich MSC Subtype Promotes Cartilage Repair in End-Stage Knee Osteoarthritis

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Mesenchymal stem cell (MSC) therapy for end-stage knee osteoarthritis (KOA) shows inconsistent efficacy, and whether MSCs retain cartilage repair capacity in the inflammatory joint remains unclear. Using single-cell RNA sequencing of human Kellgren-Lawrence grade III (G III) and IV (G IV) KOA joint tissues and exogenous MSCs, we found that pleiotrophin (PTN) signalling shifts from MSC-chondrocyte crosstalk to chondrocyte-dominated autocrine signalling, with PTN exhaustion and elevated cluster of differentiation 74 (CD74) in G IV cartilage. We therefore identified and sorted a PTN-rich CD74-low placenta-derived MSC subtype and evaluated it in a murine KOA model and in co-culture with patient-derived chondrocytes. This subtype enhanced cartilage repair, upregulated SOX9, and suppressed MMP13, CD74, IL-6, and IL-1β, potentially through CD74 suppression and reduced NF-κB signaling. These findings provide a basis for functionally defined, stage-matched cell therapy tailored to the pathological microenvironment of end-stage KOA.

HIGHLIGHTS

  • Grade IV cartilage shows pleiotrophin exhaustion and elevated CD74-driven inflammation

  • A sorted PTN-rich CD74-low placental mesenchymal stem cell subset

  • The subset reactivated endogenous chondrocyte repair, raising SOX9, lowering MMP13

  • Joint-localized cells persisted 70 days, supporting stage-matched precision therapy

Article activity feed